Proxima launches the M1 MedTech accelerator

[ad_1]

Proxima Clinical Research, a contract research organization (CRO) based at Texas Medical Center, has announced plans to launch its acceleration program – M1 MedTech early next year.

The company raised funds for company launches and investments in several new companies as part of the initial cohort.

Kevin Coker, CEO of Proxima, said: “Our goal is to substantially advance these companies in a short amount of time. Proxima is uniquely positioned to leverage our experienced team of regulatory, quality and clinical experts. We will not work remotely from these companies. We will be an important part of what they do every day ”.

M1 MedTech was created to support early stage medical device companies by delivering an immersive experience that delivers tangible benefits to participating companies. The program will involve a limited number of companies in each cohort and offer a hands-on approach to help founders advance their companies and technologies. The coaching process will include a curated educational program, interactive workshops where participants can continuously build specific business outcomes, and individual mentoring.

Larry Lawson, co-founder of Proxima, said: “This will be a unique experience for all parties involved, as Proxima is also a young, but established company, which is now creating a program to assist companies in one step. initial. Our experience in the CRO realm and the ability to provide coaching in clinical, regulatory, quality and go-to-market strategies will only strengthen M1 MedTech’s ability to support the success of emerging companies and deliver more life-saving technology to the public.

Isabella Schmitt, director of regulatory affairs at Proxima and principal of M1, added: “M1 will be a place where start-ups can receive concrete resources to further their development. Participant success is our only goal and the ultimate goal is to have a substantial impact on the design process on the market for Class II and Class III medical devices. Proxima’s specific expertise together with our M1 partners will provide resources for all key areas of a medical device entrepreneur’s journey to the market and beyond. “

For now, M1 MedTech will function as an accelerator focused on the most involved Class II and III medical devices. As the program continues to grow, the team plans to build an even larger incubator focused solely on Class III devices.

Sean Bittner, Program Director at M1 MedTech, said, “We don’t see the M1 as competitive compared to other accelerators, rather we believe it will offer a different experience. Our team will strive to create a customized program where companies have a dedicated point of contact throughout the process. We will also provide specific and customized connections and resources, verified by our team through professional partnerships, not just a general list of industry contacts ”.

M1 MedTech plans to open applications in Spring 2022. For more information on Proxima CRO and M1 MedTech, visit ProximaCRO.com or m1medtech.com.

[ad_2]